Active	Status	Sponsor type	Region	Phase	Filter
5 Active 12 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Morris, Peter
NCT05496868 / 2022-001612-25: Add-on Reparixin in Adult Patients With ARDS	Recruiting	2	66	Europe, US	Reparixin 600mg, REP, Matching Placebo, Control	Dompé Farmaceutici S.p.A, Dompè farmaceutici s.p.a.	Acute Respiratory Distress Syndrome, Adult	08/25	08/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Morris, Peter
NCT05496868 / 2022-001612-25: Add-on Reparixin in Adult Patients With ARDS	Recruiting	2	66	Europe, US	Reparixin 600mg, REP, Matching Placebo, Control	Dompé Farmaceutici S.p.A, Dompè farmaceutici s.p.a.	Acute Respiratory Distress Syndrome, Adult	08/25	08/25